

# PROGRAMA



# CLICaP

Consortio Latinoamericano para la  
Investigación del Cáncer de Pulmón

# 3<sup>er</sup>

## CONGRESO

## IBEROAMERICANO:

## Lo mejor en Cáncer de Pulmón

## 2023

---

21, 22 y 23 de febrero de 2024.



# Día 1

miércoles 21 de febrero de 2024.

8:00AM (México)

**Bienvenida.**

| Dr. Oscar Arrieta

3:00PM (España)

| Dr. Felipe Couñago

50 min.

## Cáncer de pulmón: epidemiología y tamizaje.

| Coordinador: **Dra. Lucía Viola**

10 min.

## Epidemiología.

8:10AM (México)

3:10PM (España)

- Regular Use of Pharmaceutical Opioids and Subsequent Risk of Lung Cancer WCLC 2023 MA03.08
- Profile of Reactive Estrogen Species in Women with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) WCLC 2023 OA13.04
- The Epidemiology of Young Lung Cancer: Interim Analysis of Risk Factors and Genetic Mutations WCLC 2023 OA13.06
- Pathologic and Molecular Features of Lung Adenocarcinoma in People Who Smoke and People Who Do Not Smoke WCLC 2023 ES21.05
- Rheumatoid arthritis and risk of lung cancer: a nationwide cohort study J Thorac Oncol. 2023 Oct 12:S1556-0864(23)02293-1. doi: 10.1016/j.jtho.2023.10.006.

| **Dr. Luis Seijo**

20 min.

## Tamizaje.

8:20AM (México)

3:20PM (España)

- Preliminary results from the Female Asian Nonsmoker Screening Study (FANSS). ASCO LBA 8510
- The Taiwan National Lung Cancer Screening Program WCLC 2023 PL03.04
- Performance of PLCom2012-Based Screening Eligibility in the Manchester Lung Health Check Pilot Cohort after 6 years WCLC 2023 OA07.03
- Development and Validation of a Protein-Based Lung Cancer Risk Prediction Model - Initial Results from the Lung Cancer Cohort Consortium (LC3) WCLC 2023 OA07.06
- Effectiveness of NELSON versus PLCom2012 Lung Cancer Screening Eligibility Criteria: First Results from the German HANSE Study WCLC 2023 OA07.04

| **Dra. Renata Báez**

8:30AM (México)

3:30PM (España)

- Newly diagnosed non-small cell lung cancer with interstitial lung abnormality: Prevalence, characteristics, and prognosis. doi: 10.1111/1759-7714.14935
- Low-Dose Computed Tomography Screening in Relatives with a Family History of Lung Cancer doi: 10.1016/j.jtho.2023.06.018.
- Molecular Distribution of Patients with Non-Small Cell Lung Cancer Eligible for Lung Cancer Screening WCLC 2023 MA02.06
- Pack-Year Smoking History Is an Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility WCLC 2023 MA02.08
- Assessing the Impact of Increasing Lung Screening Eligibility by Relaxing the Maximum Years since Quit Threshold. A Simulation Modeling Study WCLC 2023 OA16.05

| **Dra. Marisol Arroyo**

10 min.

## Tamizaje e inteligencia artificial.

## PROGRAMA

### 3<sup>er</sup> CONGRESO IBEROAMERICANO: Lo mejor en Cáncer de Pulmón 2023

8:40AM   
(México)


3:40PM   
(España)

- AI Can Greatly Reduce Radiologist Workload if Used as a First Read Filter to Rule-Out Negative Cases in Lung Cancer Screening WCLC 2023 MA19.08 –
- Predicting Future Lung Cancer Risk with Low-Dose Screening CT Using an Artificial Intelligence Model WCLC 2023 MA19.11
- Artificial Intelligence as Concurrent Reader in Prospective European Lung Cancer Screening (4-IN-THE-LUNG-RUN) Trial WCLC 2023 MA19.06 –
- Cost-Consequence Analysis of Artificial Intelligence Assisted Image Reading in Lung Cancer Screening WCLC 2023 EP04.02-03
- Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography. J Clin Oncol. 2023 Apr 20;41(12):2191-2200. doi: 10.1200/JCO.22.01345.

| Dr. Luis Eduardo Pino

8:50AM   
(México)

3:50PM   
(España)

10 min. 

**Discusión.**

| Todos


9:00AM   
(México)

4:00PM   
(España)

60 min. 

**Cáncer de pulmón en etapas tempranas: etapificación y cirugía. Coordinador:**

| Coordinador: Dra. Stella Isabel Martínez

10 min. 

**Etapificación TNM novena edición.**

9:00AM   
(México)

4:00PM   
(España)

10 min. 

**9th Edition TNM Staging Classification: Lung Cancer WCLC 2023 PL04.03 –**

| Dr. Ramón Rami Porta

**Etapificación.**


9:10AM   
(México)

4:10PM   
(España)

15 min. 

- Endosonography With or Without Confirmatory Mediastinoscopy for Resectable Lung Cancer: A Randomized Clinical Trial. doi: 10.1200/JCO.22.01728
- Approach to Multistation Lymph Node Staging and Multifocal NSCLC WCLC 2023 ES04.05
- N0/1 Staging for Limited Resection and Resectable N2 NSCLC WCLC 2023 ES04.06 –
- Novel Classification with Number or Zones of Involved Lymph Nodal Stations in Patients with Resected Non-Small Cell Lung Cancer WCLC 2023 MA21.04

| Dr. Néstor Martínez

15 min. 

**Cirugía.**

9:20AM   
(México)


4:20PM   
(España)

15 min. 

- An Analysis of the Rate of Second Primary Lung Cancer from CALGB (Alliance) 140503 Trial of Lobar versus Sub-Lobar Resection for T1aN0 NSCLC WCLC 2023
- Surgical Outcomes with Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC (AEGEAN) Segmentectomy is Supported as Standard of Care for Small, Peripheral Non-Small-Cell Lung Cancer WCLC 2023 Abstract OA12.05 –
- Selective Mediastinal Lymph Node Dissection Strategy for Clinical T1N0 Invasive Lung Cancer: A Prospective, Multicenter, Clinical Trial DOI 10.1016/j.jtho.2023.02.010.
- Reassessing Sublobar vs. Lobar Resection for Early-stage Small Cell Lung Cancer in the Wake of CALGB 140503 WCLC 2023 MA18.06
- Sublobar Resection vs. Lobectomy for Non-Small-Cell Lung Cancers 2cm or Less in Size with High-Risk Features WCLC 2023 OA11.06 –
- Lymph node dissections and survival in sublobar resection of non-small cell lung cancer ≤ 20 mm doi: <https://doi.org/10.1007/s11748-022-01876-6>

| Dr. Juan Carlos Trujillo

**PROGRAMA**
**3<sup>er</sup> CONGRESO IBEROAMERICANO:  
Lo mejor en Cáncer de Pulmón  
2023**

 15 min. 
**Papel de la biopsia líquida en etapa temprana.**

 9:35AM   
(México)

**Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase 3 AEGEAN trial ESMO LBA59 -**

 4:35PM   
(España)


| \* POR CONFIRMAR

 9:50AM   
(México)

**Discusión.**

 4:50PM   
(España)

| Todos

 10 min. 

 20 min. 
**Conferencia magistral.**

 10:00AM   
(México)

**Cirugía robótica uniportal.**

 5:00PM   
(España)


| Dr. Diego González Rivas

 10:20AM   
(México)

**Neoadyuvancia en CPCNP no mutados.**

 5:20PM   
(España)

| Coordinador: Dr. Luis Mas

 60 min. 


 20 min. 
**Neoadyuvancia en CPCNP no mutados – parte I.**

 10:20AM   
(México)

 5:20PM   
(España)

- Perioperative toripalimab + platinum doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study ASCO Abstract 8501
- AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC AACR Abstract AACR CT005
- Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC) ESMO LBA56
- CheckMate 77T: Phase 3 study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIB NSCLC ESMO LBA1
- Pathological Response to Neoadjuvant Tislelizumab (TIS) Plus Platinum-Doublet (PtDb) Chemotherapy (CT) in Resectable Stage II-III NSCLC Patients (pts) in the Phase 3 (Ph3) RATIONALE-315 Trial ESMO LBA58

| Dr. Oscar Arrieta

 20 min. 
**Neoadyuvancia en CPCNP no mutados – parte II.**

 10:40AM   
(México)


 5:40PM   
(España)

- Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase 3 CheckMate 816 trial ESMO 12610
- Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase 3 CheckMate 816 study: 3-y results by tumor PD-L1 expression ESMO LBA57
- Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial doi: 10.1038/s41591-022-02189-0.
- Pembrolizumab and ramucirumab neoadjuvant therapy for PD-L1-positive stage IB-III A lung cancer (EAST ENERGY). ASCO Abstract 8509
- Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non-Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial. doi: 10.1001/jamaoncol.2023.2751.

| Dr. Bartomeu Massuti

## PROGRAMA

# 3<sup>er</sup> CONGRESO IBEROAMERICANO: Lo mejor en Cáncer de Pulmón 2023

10 min. 

### Patología.

11:00AM   
(México)


6:00PM   
(España)

- International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy DOI:10.1016/j.jtho.2023.09.1446
- Evaluation of Pathological Tumor and Nodal Responses Following Neoadjuvant Chemoimmunotherapy in NSCLC Patients WCLC 2023 OA15.03
- Differences in Pathologic Assessment by MPR Calculation Methods for Multiple Slides of Tumor Bed in SQUAT Trial (WJOG12119L) WCLC 2023 OA15.06 –

| Dr. Fernando López-Ríos

11:10AM   
(México)

6:10PM   
(España)


10 min. 

### Discusión.

| Todos


11:20AM   
(México)

6:20PM   
(España)

30 min. 

### Adyuvancia en CPCNP no mutados.

| Coordinador: Dr. Luis Corrales

20 min. 

### Adyuvancia en CPCNP no mutados.

11:20AM   
(México)


6:20PM   
(España)

- Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIa non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial DOI: 10.1016/j.annonc.2023.07.001.
- IMpower010: exploratory analysis of disease-free survival (DFS) by TGF $\beta$  cancer-associated fibroblast (CAF) gene signature expression in patients (pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive care (BSC) ESMO 1264MO
- IMpower010: Exploratory Analysis of Tumor Mutational Burden and Disease-Free Survival with Adjuvant Atezolizumab in NSCLC WCLC MA11.08
- Pembrolizumab vs placebo for early-stage non-small-cell lung cancer after resection and adjuvant therapy: Subgroup analysis of patients who received adjuvant chemotherapy in the phase 3 PEARLS/KEYNOTE-091 study. ASCO 8520
- Updated survival, efficacy and safety of adjuvant (adj) atezolizumab (atezo) after neoadjuvant (neoadj) atezo in the phase II LCMC3 study ELCC 145MO

| Dr. Enric Carcereny


11:40AM   
(México)

6:40PM   
(España)

10 min. 

### Discusión.

| Todos

20 min. 

### Mesa de debate.

| Coordinadora: Dra. Enriqueta Felip

11:50AM   
(México)

6:50PM   
(España)

### Neoadyuvancia vs. adyuvancia en CPCNP EC IB – IIIA sin *drivers* oncogénicos.

| Dr. Ernest Nadal  
| Dr. Mariano Provencio

30 min.

**CPCNP neo y adyuvancia EGFR/ALK.**

 | Coordinador: **Dr. Froylan López**

 12:10PM  
 (México)

 7:10PM  
 (España)

- Overall survival analysis from the ADAURA trial of adjuvant Osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC). doi: 10.1056/NEJMoa2304594
- Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR-mutated non-small cell lung cancer ASCO Abstract 8508
- Drug Tolerant Persister Cells to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer Harboring EGFR Mutations (NORA) WCLC 2023 MA11.11
- Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Resectable EGFR-mutated NSCLC (AEGEAN) WCLC OA12.05
- ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC) ESMO LBA2
- Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis doi: 10.1038/s41698-022-00301-8.

 | **Dra. Carmen Pupareli**

 12:30PM  
 (México)

 7:30PM  
 (España)

10 min.

**Discusión.**

 | **Todos**

15 min.

**Mesa de debate.**

 | Coordinador: **Dra. Dolores de la Mata**

 12:40PM  
 (México)

 7:40PM  
 (España)

**Radioterapia postoperatoria en la era de inmunoterapia y terapia dirigida.**

 | **Dra. Mónica Blake**  
 | **Dr. José M. Barros**

 12:55PM  
 (México)

 7:55PM  
 (España)

10 min.

**Break**

 | **Todos**

 1:05PM  
 (México)

 8:05PM  
 (España)

30 min.

**CPCNP etapa IIIA (N2).**

 | Coordinador: **Dra. Esther Holgado**

20 min.




**Resecabilidad en CPCNP EC III.**

 1:05PM  
 (México)

 8:05PM  
 (España)

- The TNM System Is Not Adequate to Guide Lung Cancer Multidisciplinary Teams in Treatment Decisions in the Precision Oncology Era. doi: 10.1016/j.jtho.2022.08.006
- An International EORTC Survey on Resectability of Stage III Non-small Cell Lung Cancer WCLC 2023 OA06.03 -
- Consensual definition of stage III NSCLC Resectability: EORTC-Lung Cancer Group initiative with other scientific societies WCLC 2023 OA06.05

 | **Dr. Francisco Corona**

**PROGRAMA****3<sup>er</sup> CONGRESO IBEROAMERICANO:**  
Lo mejor en Cáncer de Pulmón  
**2023**1:25PM   
(México)**Discusión.**8:25PM   
(España)| **Todos**10 min. 20 min. **Mesa de debate.**| **Coordinador: Dr. Enrique Guzmán**1:35PM   
(México)**Manejo y controversias en el manejo del CPCNP EC III:  
Abordaje quirúrgico vs. no quirúrgico.**8:35PM   
(España)| **Dr. Jesús Corral**  
| **Dr. Felipe Couñago**1:55PM   
(México)**Cierre de jornada e introducción al siguiente día.**8:55PM   
(España)| **Dr. Felipe Couñago**



## Día 2

jueves 22 de febrero de 2024.

8:00AM (México)

**Bienvenida e introducción al día 2.**  
| Dr. Oscar Arrieta

3:00PM (España)

20 min.

**Radioterapia en etapa temprana.**

| Coordinador: Dr. Iván Bobadilla

8:10AM (México)

3:10PM (España)

- Stereotactic body radiation therapy with sequential immunochemotherapy as neoadjuvant therapy in resectable non-small cell lung cancer ESMO LBA60
- I-SABR: Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial DOI: 10.1016/S0140-6736(23)01384-3.
- SAKK 16/18: Neoadjuvant Chemotherapy, Durvalumab and Immune-Modulatory RT in Stage III(N2) NSCLC. Surgical Interim Analysis. WCLC 2023 MA11.09 -
- Surgery after Neoadjuvant Immuno-Chemoradiotherapy in (Borderline) Resectable NSCLC: Results from the INCREASE Trial WCLC 2023 OA06.04 -
- A Propensity-Matched Comparison between Minimally Invasive Surgery and Stereotactic Radiotherapy in the Treatment of Clinical Stage I NSCLC WCLC 2023 OA11.05 –
- Prospective Cohort Study to Compare Long-Term Lung Cancer-Specific and All-Cause Survival of Clinical Early Stage (T1a–b; ≤20 mm) NSCLC Treated by Stereotactic Body Radiation Therapy and Surgery DOI:https://doi.org/10.1016/j.jtho.2023.10.002

| Dra. Marian Gómez Aparicio

8:30AM (México)

**Discusión.**

3:30PM (España)

| Todos

10 min.

20 min.

**Mesa de debate.**

| Coordinador: Dr. Francisco Lozano

8:40AM (México)

**SBRT vs. tratamiento quirúrgico en enfermedad temprana.**

3:40PM (España)

| Dra. Raquel Ciérvide  
| Dr. Arturo Navarro  
| Dra. Vanessa Cores

30 min.

**Terapias de soporte en CPCNP.**

| Coordinador: Dr. Carlos Aliaga

9:00AM (México)

4:00PM (España)

- The Effect of Chronic Psychological Stress on the Efficacy of First-line Therapy of ICIs in advanced NSCLC (STRESS-LUNG-1 Trial) ESMO 1843MO –
- Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers The TARGET-TP Randomized Clinical Trial doi:10.1001/jamaoncol.2023.3634
- Anamorelin and weight gain in patients with advanced Non Small Cell Lung Cancer (NSCLC) and cachexia: efficacy and safety in the multinational phase 3 SCALA program ESMO LBA95
- Randomized Phase II Study of Zoledronate Dosing Every 4 Versus 8 Weeks in Patients With Bone Metastasis From Lung Cancer (Hanshin Cancer Group 0312) WCLC 2023 MA01.04



## PROGRAMA

### 3<sup>er</sup> CONGRESO IBEROAMERICANO: Lo mejor en Cáncer de Pulmón 2023

- Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer doi: 10.1200/JCO.22.01997.
- Sexual Health Assessment in Women with Lung Cancer study: Sexual health assessment in women with lung cancer. Cancer. 2023 Oct 16. doi: 10.1002/cncr.35057.


| Dr. David Dávila

9:20AM   
(México)

**Discusión.**

4:20PM   
(España)

| Todos

10 min. 

30 min. 

**CPCNP localmente avanzado irreseccable.**

| Coordinador: Dr. Federico Maldonado

9:30AM   
(México)

- Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy of radiochemotherapy (RCT) in patients with inoperable stage III non-small cell lung cancer (RTEP7 – IFCT 1401): a prospective multicentre, open-label, randomised, controlled trial. ESMO 1291O
- Safety and efficacy of hypo- and conventionally fractionated thoracic radiotherapy plus durvalumab in elderly or frail NSCLC stage III patients unfit for chemotherapy – interim results from the TRADE-hypo trial ESMO 1293MO
- Durvalumab after radiotherapy (RT) in patients with unresectable Stage III NSCLC ineligible for chemotherapy (CT): Primary results from the DUART study ESMO LBA62
- A phase II study of daily carboplatin plus irradiation followed by durvalumab for unresectable III non-small cell lung cancer patients with PS 2 or elderly ( ≥ 75 years): NEJ039A ESMO 1292MO
- Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable Stage III NSCLC: Final analysis from PACIFIC-6: ESMO LBA61
- Real-World Outcomes with Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC (PACIFIC-R) WCLC 2023 OA17.03 -
- Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non–Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial. JAMA Oncol. 2023 Sep 7:e233309. doi: 10.1001/jamaoncol.2023.3309.

| Dr. David Vicente Baz


9:50AM   
(México)

**Discusión.**

4:50PM   
(España)


| Todos

10 min. 

50 min. 

**CPCNP avanzado no mutados.**

| Coordinador: Dr. Diego Díaz

10 min. 

**Inmunoterapia 1ª línea – parte I.**

10:00AM   
(México)

- EMPOWER-Lung 1: Cemiplimab (CEMI) monotherapy as first-line (1L) treatment of patients (pts) with brain metastases from advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% — 3-year update ELCC 10MO
- A Phase 3 Study of Serplulimab Plus Chemotherapy as First-Line Treatment for Squamous Non-small-Cell Lung Cancer (ASTRUM-004) WCLC OA09.05
- Six-year Survival and HRQoL Outcomes with 1L Nivolumab + Ipilimumab in Patients with Metastatic NSCLC from CheckMate227 WCLC 2023


5:00PM   
(España)

## PROGRAMA

### 3<sup>er</sup> CONGRESO IBEROAMERICANO: Lo mejor en Cáncer de Pulmón 2023

- Three-Year Outcomes with First-Line Pembrolizumab, in Patients with Non-Small-Cell Lung Cancer and A PD-L1 Tumor Proportion Score >90% WCLC 2023 OA14.04
- 5-Year Survival of Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With PD-L1 Tumor Proportion Score <1% WCLC 2023 OA14.05

| Dr. Claudio Martin

10 min. 


#### Inmunoterapia 1ª línea – parte II.

10:10AM   
(México)

5:10PM   
(España)


- First-line immune checkpoint inhibitors alone or in combination with chemotherapy in real-life elderly patients with advanced non-small cell lung cancer (NEJ057). ASCO Abstract 9012
- Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05). doi: 10.1200/JCO.22.02561
- Overall Survival from a Phase II Randomised Double-Blind Trial (PERLA) of Dostarlimab (dostar) + Chemotherapy (CT) vs Pembrolizumab (pembro) + CT in Metastatic Non-Squamous NSCLC ESMO LBA64
- Combining the antigen-presenting cell activator eflilagimod alpha (soluble LAG-3) and pembrolizumab: overall survival data from the 1st line non- small cell lung carcinoma (NSCLC) cohort of TACTI-002 (Phase II) ESMO 1312MO –
- First-line immune checkpoint inhibitors alone or in combination with chemotherapy in real-life elderly patients with advanced non-small cell lung cancer (NEJ057). ASCO Abstract 9012
- Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05). doi: 10.1200/JCO.22.02561
- Overall Survival from a Phase II Randomised Double-Blind Trial (PERLA) of Dostarlimab (dostar) + Chemotherapy (CT) vs Pembrolizumab (pembro) + CT in Metastatic Non-Squamous NSCLC ESMO LBA64
- Combining the antigen-presenting cell activator eflilagimod alpha (soluble LAG-3) and pembrolizumab: overall survival data from the 1st line non- small cell lung carcinoma (NSCLC) cohort of TACTI-002 (Phase II) ESMO 1312MO -

| Dr. Carlos Camps Herrero

10 min. 


#### Inmunoterapia en líneas subsecuentes.

10:20AM   
(México)

5:20PM   
(España)

- SAPPHERE: Phase 3 Study of Sitravatinib Plus Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) ESMO LBA063
- Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB–IV non-small-cell lung cancer (NSCLC) with previous anti-PD-(L)1 therapy ESMO 1313MO
- A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630. doi: 10.1158/1078-0432.CCR-22-1687
- Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study). doi: 10.1016/j.ejca.2023.01.025.

| Dr. Leonardo Rojas

10 min. 

#### ADCs en CPCNP sin alteraciones genómicas accionables.

10:30AM   
(México)

5:30PM   
(España)

- Datopotamab Deruxtecan (Dato-DXd) + Durvalumab ± Carboplatin in Advanced/mNSCLC: Initial Results from Phase 1b TROPION-Lung04 WCLC 2023 OA05.06
- Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): results of the randomized phase 3 study TROPION-Lung01
- Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study WCLC 2023 OA05.04
- Safety and efficacy of tusamitamab ravtansine in combination with pembrolizumab ± chemotherapy in patients with CEACAM5-positive nonsquamous NSCLC (CARMEN-LC05 phase II study) ELCC 13MO


| Dr. Delvys Rodríguez

10:40AM   
(México)

5:40PM   
(España)

#### Discusión.

| Todos

10 min. 

**PROGRAMA**
**3<sup>er</sup> CONGRESO IBEROAMERICANO:  
Lo mejor en Cáncer de Pulmón  
2023**

30 min.

**CPCNP avanzado: EGFR 1<sup>a</sup> línea.**

 | Coordinador: **Dr. Enrique Caballé**

10 min.

**EGFR-TKI + quimioterapia.**

 10:50AM  
(México)

 5:50PM  
(España)

- Osimertinib With / Without Platinum-Based Chemotherapy as First-Line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2) WCLC 2023
- FLAURA2: safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC ESMO LBA68
- A phase III study comparing EGFR tyrosine kinase inhibitor (EGFR-TKI) monotherapy and EGFR-TKI with inserted cisplatin (CDDP) plus pemetrexed (PEM) as a first-line treatment in patients (pts) with advanced non-squamous non-small-cell lung cancer (NSqNSCLC) harboring EGFR activating mutation (EGFR- NSqNSCLC): JCOG1404/WJOG8214L, AGAIN study. ASCO LBA 9009
- Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study doi: 10.1016/j.clcc.2020.09.023.

 | **Dr. Luis Raez**

10 min.

**EGFR-TKI + antiangiogénicos/Ac. biespecíficos.**

 11:00AM  
(México)

 6:00PM  
(España)

- OSIRAM-1: A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer (TORIG1833) ESMO LBA70 –
- Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation positive locally advanced or metastatic non-small cell lung cancer (NSCLC): a randomized multicenter study ESMO LBA69
- Aumolertinib Plus Anlotinib in Advanced NSCLC with Brain Metastasis: A Single-arm, Phase II Study WCLC 2023 OA03.03 –
- A Multi-Centre Open-Label Randomized Phase II Study of Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Metastatic NSCLC (RAMOSE trial interim analysis) ESMO LBA71
- Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment in Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From MARIPOSA, a Phase 3, Global, Randomized, Controlled Trial ESMO LBA14

 | **Dra. Margarita Majem**

 11:10AM  
(México)

 6:10PM  
(España)

**Discusión.**

 | **Todos**

10 min.

15 min.

**Mesa de debate.**

 | Coordinador: **Dr. Ludwing Bacon Fonseca**

 11:20AM  
(México)

 6:20PM  
(España)

**Estándar de tratamiento en primera línea en pacientes con CPCNP EGFR mutado: EGFR-TKI monoterapia vs. combos**

 | **Dr Mikel Rico**  
| **Dr. Enrique Caballé**

40 min.

**CPCNP avanzado: EGFR en líneas subsecuentes.**

 | Coordinador: **Dr. Luis Lara**


10 min.

**Ac. biespecíficos + quimioterapia.**

## PROGRAMA


### 3<sup>er</sup> CONGRESO IBEROAMERICANO: Lo mejor en Cáncer de Pulmón 2023

11:35AM   
(México)

6:35PM   
(España)


- Amivantamab Plus Chemotherapy (With or Without Lazertinib) vs Chemotherapy in EGFR-mutated Advanced NSCLC After Progression on Osimertinib: MARIPOSA-2, a Phase 3, Global, Randomized, Controlled Trial ESMO LBA15
- Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: Analysis of tissue IHC and ctDNA NGS. ASCO abs 9013

| Dr. Edgar Varela

10 min. 

**Inmunoterapia en EGFR.**

11:45AM   
(México)

6:45PM   
(España)


- A Phase 3, Randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATLAS, KCSG-LU19-04) ESMO LBA67
- Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial DOI: 10.1016/S2213-2600(23)00135-2.
- Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study. ASCO
- IMpower151: Phase III Study of Atezolizumab + Bevacizumab + Chemotherapy in 1L Metastatic Nonsquamous NSCLC WCLC 2023 OA09.06
- ILLUMINATE: Efficacy and Safety of Durvalumab-Tremelimumab and Chemotherapy in EGFR Mutant NSCLC Following Progression on EGFR Inhibitors WCLC 2023 OA09.04 –

| Dr. Lisardo Ugidos

10 min. 

**ADCs en CPCNP con alteraciones genómicas accionables.**

11:55AM   
(México)


6:55PM   
(España)

- TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs) ESMO 1314MO –
- Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFR TKI and Platinum-Based Chemotherapy: HERTHENA-Lung01 DOI: 10.1200/JCO.23.01476
- Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: results from HERTHENA-Lung01 DOI: 1319MO –
- Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. DOI: 10.1200/JCO.22.00739

| Dra. Rosario García Campelo

12:05PM   
(México)

7:05PM   
(España)

10 min. 

**Discusión.**

| Todos

30 min. 


**CPCNP avanzado: EGFR exon 20 y cMET.**

| Coordinador: Dr. Carlos Izquierdo

20 min. 

**CPCNP avanzado: EGFR exon 20 y cMET.**

12:15PM   
(México)

7:15PM   
(España)


- Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Treatment in EGFR Exon 20 Insertion-mutated Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From PAPILLON, a Randomized Phase 3 Global Study ESMO LBA5
- WU-KONG6 Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results. ASCO 9002
- Safety, Tolerability, and Antitumor Activity of Ziplertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions DOI: 10.1200/JCO.23.00152
- A Phase 1b Study Of Furmonertinib, an Oral, Brain Penetrant, Selective EGFR Inhibitor, in Patients with Advanced NSCLC with EGFR Exon 20 Insertions WCLC 2023 OA03.04

## PROGRAMA


### 3<sup>er</sup> CONGRESO IBEROAMERICANO: Lo mejor en Cáncer de Pulmón 2023

- Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study WCLC 2023
- Tepotinib + Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis WCLC 2023 OA21.05
- A Phase 3b Study of 1L Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 Mutation WCLC 2023 OA21.03


| Dr. Rafael López Castro


12:35PM   
(México)

**Discusión.**


7:35PM   
(España)

| Todos


10 min. 


12:45PM   
(México)

**Break.**

7:45PM   
(España)


| Todos

10 min. 

30 min. 

**CPCNP avanzado: KRAS.**

| Coordinador: Dr. Víctor Oyervides

20 min. 

**KRAS.**


12:55PM   
(México)

- KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation ESMO LBA65
- The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer with KRAS G12C mutation (WJOG14821L).
- Biomarker subgroup analyses of CodeBreak200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). ASCO 2023
- CodeBreak 101: Safety and Efficacy of Sotorasib with Carboplatin and Pemetrexed in KRAS G12C-Mutated Advanced NSCLC. WCLC 2023 MA06.05
- KRYSTAL-1: Two-Year Follow-Up of Adagrasib (MRTX849) Monotherapy in Patients with Advanced/Metastatic KRASG12C-Mutated NSCLC – WCLC 2023 MA06.04
- KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors WCLC 2023 MA06.03
- Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. DOI: 10.1056/NEJMoa2303810
- Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer. doi: 10.1016/j.jtho.2023.05.013
- A Phase II Trial of Ceralasertib and Durvalumab in Advanced Non-Small Cell Lung Cancer (NSCLC) with and without RAS Mutations: Results of NLMT Arm J WCLC 2023 MA06.06


| Dra. Ivana Sullivan

1:15PM   
(México)

**Discusión.**

8:15PM   
(España)

| Todos

10 min. 

40 min.

**CPCNP avanzado: otros drivers.**

 | Coordinador: **Dra. Tannia Soria**

30 min.

**Otros drivers.**

 1:25PM  
 (México)

 8:25PM  
 (España)

- Updated efficacy and safety of taletrectinib in patients (pts) with ROS1+ non-small cell lung cancer (NSCLC) ELCC 14MO
- Randomized Phase 3 Study of First-line Selpercatinib versus Chemotherapy and Pembrolizumab in RET Fusion-positive NSCLC ESMO LBA4
- Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial. doi: 10.1200/JCO.23.01361
- Efficacy and Safety of Pozitotinib in HER2 Exon 20 Insertion NSCLC Patients who Received at Least 2 Previous Systemic Therapies WCLC 2023 MA13.09
- Trastuzumab Deruxtecan (T-DXd) in Patients (pts) With HER2 (ERBB2)-Mutant (HER2m) Metastatic Non-Small Cell Lung Cancer (NSCLC) With and Without Brain Metastases (BMs): Pooled Analyses From DESTINY-Lung01 and DESTINY-Lung02 ESMO 1321MO
- Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a Phase I study with BAY 2927088 ESMO 1320MO
- Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
- Repotrectinib in Patients with ROS1 Fusion-positive (ROS1+) NSCLC: Update from the Pivotal Phase 1/2 TRIDENT-1 Trial WCLC 2023 OA03.06 –
- Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer. doi: 10.1200/JCO.23.00774.

 | **Dr. Rafael Rosell**

 1:55PM  
 (México)

 8:55PM  
 (España)

10 min.

**Discusión.**

 | **Todos**

30 min.

**CPCNP avanzado: ALK.**

 | Coordinador: **Dra. Pilar Garrido**

20 min.

**ALK.**

 2:05PM  
 (México)

 9:05PM  
 (España)

- Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial DOI: <https://doi.org/10.1016/j.jtho.2023.08.010>
- Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib doi: 10.1016/j.jto.2022.100311.
- Analysis of Serious Weight Gain in Patients Using Alectinib for ALK-Positive Lung Cancer. doi: 10.1016/j.jtho.2023.03.020
- Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations doi: 10.1016/j.jtho.2023.07.023.
- Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC doi: 10.1016/j.jtho.2023.05.021.
- A Randomized, Phase 3 Study of Irupinalkib (WX-0593) vs Crizotinib in Locally Advanced or Metastatic ALK+ Non-small Cell Lung Cancer (NSCLC) WCLC 2023
- Lorlatinib for Previously Treated ALK-positive Advanced NSCLC: Updated Efficacy and Safety Data from a Phase 2 Study in China WCLC MA06.11

 | **Dr. Saúl Campos**

## PROGRAMA


# 3<sup>er</sup> CONGRESO IBEROAMERICANO: Lo mejor en Cáncer de Pulmón 2023

2:25PM   
(México)

Discusión.


9:25PM   
(España)

| Todos

10 min. 

2:35PM   
(México)

Cierre de jornada e introducción siguiente día.














9:35PM   
(España)

| Dr. Felipe Couñago



# Día 3

viernes 23 de febrero de 2024.

<p>8:00AM  (México)</p> <p>3:00PM  (España)</p>	<p><b>Bienvenida e introducción al día 3.</b>   Dr. Oscar Arrieta</p>
<p>40 min. </p>	<p><b>CPCNP: Radioterapia en enfermedad avanzada.</b>   Coordinador: Dr. Abrahams Ocanto</p>
<p>30 min. </p>	<p><b>Radioterapia en enfermedad avanzada.</b></p>
<p>8:10AM  (México)</p> <p>3:10PM  (España)</p>	<ul style="list-style-type: none"> <li>• The Addition of Multisite SBRT to Ipilimumab and Nivolumab in First Line Metastatic NSCLC: The COSINR Trial WCLC 2023 OA22.03 –</li> <li>• Concurrent Radiation and Immunotherapy Augments Local Immunity and Improves Survival in Aneuploid NSCLC</li> <li>• BRIGHTSTAR Local Consolidative Therapy with Brigatinib in Tyrosine Kinase Inhibitor-Naïve ALK-Rearranged Metastatic NSCLC WCLC 2023 OA22.04</li> <li>• Changes in Cognition after Osimertinib, with or without SRS, in EGFRm NSCLC with Brain Metastases: a Pooled Analysis of RCTs WCLC 2023 OA22.06</li> <li>• Circulating Tumor DNA for Early Risk Stratification of Oligometastatic Lung Cancer ASTRO 2023</li> <li>• Genomic Signature for Oligometastatic Disease in Non-Small Cell Lung Cancer Patients with Brain Metastases ASTRO 2023</li> <li>• Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study ASCO 2023</li> </ul> <p>  Dra. Margarita Martín</p>
<p>8:40AM  (México)</p> <p>3:40PM  (España)</p> <p>10 min. </p>	<p><b>Discusión.</b>   Todos</p>
<p>60 min. </p>	<p><b>Lo Mejor de ASTRO 2023.</b>   Coordinador: Dra. Verónica Vázquez Balcarce</p>
<p>25 min. </p>	<p><b>Parte I: CPCNP.</b></p>
<p>8:50AM  (México)</p> <p>3:50PM  (España)</p>	<ul style="list-style-type: none"> <li>• Prospective Phase II Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy (SBRT) Followed By Concurrent Mediastinal Chemoradiation and Adjuvant Immunotherapy for Locally-Advanced Non-Small Cell Lung Cancer (LA NSCLC) ASTRO 2023</li> <li>• A Multicentered, Randomized Phase III Study of Definitive vs. Palliative Radiotherapy to Primary Tumor for Stage IV Non-Small Cell Lung Cancer with Less than Three Metastatic Organs: CSWOG China ASTRO 2023</li> <li>• Adaptive Radiotherapy Guided by PET/CT in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Phase II Randomized Study ASTRO 2023</li> <li>• Residual ctDNA Detection Predicts Benefit From Definitive Chemoradiotherapy and Immune Checkpoint Inhibitors in Locally Advanced NSCLC ASTRO 2023</li> <li>• Early Stereotactic Body Radiotherapy to the Primary Lung Lesion for Patients with Advanced NSCLC Treated with First-Line Systemic Therapy ASTRO 2023</li> </ul> <p>  Dr. Rodolfo Chicas</p>





25 min.	<b>Parte II: CPCP.</b>
<p>9:15AM  (México)</p> <p>4:15PM  (España)</p>	<ul style="list-style-type: none"> <li>Stereotactic Radiotherapy vs. Whole Brain Radiation Therapy for Patients with 1-10 Brain Metastases from Small Cell Lung Cancer: Results of the Randomized ENCEPHALON (ARO 2018-9) Trial ASTRO 2023</li> <li>High Dose Hyperfractionated Thoracic Radiotherapy vs. Standard Dose for Limited Stage Small-Cell Lung Cancer: A Multicenter, Open-Label Randomized, Phase 3 Trial ASTRO 2023</li> <li>Thoracic Radiotherapy Improves the Outcomes of Extensive Stage Small-Cell Lung Cancer Patients Receiving First-Line Immunotherapy: A Multicenter Retrospective Analysis ASTRO 2023</li> <li>30 Gy vs. 45 Gy Consolidative Thoracic Radiation (cTRT) for Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Multicenter, Randomized, Phase 3 Trial ASTRO 2023</li> <li>PD-L1 Inhibitors Combined with Thoracic Radiotherapy in First-Line Treatment of Extensive Stage Small Cell Lung Cancer: A Propensity Score-Matched, Real-World Study ASTRO 2023</li> <li>Primary Endpoint Results of NRG CC003: Phase IIR/III Trial of Prophylactic Cranial Irradiation (PCI) with or without Hippocampal Avoidance (HA) for Small Cell Lung Cancer (SCLC) ASTRO 2023 LBA 04</li> </ul> <p>  Dr. José Luis López Guerra</p>
<p>9:40AM  (México)</p> <p>4:40PM  (España)</p>	<p><b>Discusión.</b></p> <p>  Todos</p>
30 min.	<p><b>Papel de la radioterapia en CPCP.</b></p> <p>  Coordinador: Dr. Gustavo Ferraris</p>
<p>9:50AM  (México)</p> <p>4:50PM  (España)</p>	<ul style="list-style-type: none"> <li>Efficacy of Prophylactic Cranial Irradiation According to the Risk of Extracranial Recurrence in Limited-Stage Small Cell Lung Cancer WCLC 2023 EP13.04-0</li> <li>Preliminary Results of a Prospective Trial of Hypofractionated Radiotherapy Versus Hyperfractionated Radiotherapy for Limited-stage SCLC WCLC EP13.04-04 –</li> <li>The Impact of PCI on the Prognosis of Limited-stage SCLC Patients in the Era of MRI Surveillance WCLC 2023 EP13.04-03 –</li> <li>The Impact of Prophylactic Cranial Irradiation and Consolidative Thoracic Radiation Therapy for Extensive Stage Small Cell Lung Cancer in the Transition to the Chemo-immunotherapy Era: A Single Institution Series. DOI:https://doi.org/10.1016/j.clc.2023.08.009</li> <li>Preliminary Safety and Treatment Data of A Phase 3 Trial: Hypofractionated vs Conventional Fractionated Concurrent Chemoradiation for LS-SCLC WCLC 2023 MA18.03</li> <li>Prognostic Factors in Limited-Stage Small Cell Lung Cancer (LSCLC) : Secondary Analysis of CALGB 30610 (Alliance)/RTOG 0538 WCLC 2023 MA18.04</li> </ul> <p>  Dra. Paloma Sosa Fajardo</p>
<p>10:10AM  (México)</p> <p>5:10PM  (España)</p>	<p><b>Discusión.</b></p> <p>  Todos</p>
<p>10:20AM  (México)</p> <p>5:20PM  (España)</p> <p>10 min. </p>	<p><b>Break</b></p> <p>  Todos</p>



**PROGRAMA**

**3er CONGRESO IBEROAMERICANO:  
Lo mejor en Cáncer de Pulmón  
2023**

60 min.	<b>Tratamiento sistémico en CACP.</b>   Coordinador: <b>Dr. Luis Cabrera</b>
30 min.	<b>Primera línea.</b>
10:30AM  (México) 5:30PM  (España)	<ul style="list-style-type: none"> <li>Sacituzumab govitecan (SG) as second-line (2L) treatment for extensive stage small cell lung cancer (ES-SCLC): Preliminary results from the phase 2 TROPiCS-03 basket trial ESMO 1990MO</li> <li>EXTENTORCH: a randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC) ESMO LBA93</li> <li>Benmelstobart with Anlotinib plus Chemotherapy as First-line Therapy for ES-SCLC: A Randomized, Double-blind, Phase III Trial WCLC OA01.03 –</li> <li>Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results WCLC 2023 OA01.04</li> <li>Phase I Dose Escalation Trial Of The DLL3/CD3 Igg-Like T Cell Engager BI 764532 In Patients with DLL3+ Tumors: Focus on SCLC WCLC 2023 OA01.05</li> <li>SWOG S1929: Phase II randomized study of maintenance atezolizumab(A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC). ASCO 2023</li> <li>First-Line Chemotherapy With or Without Tislelizumab for Extensive-Stage Small Cell Lung Cancer: RATIONALE-312 Phase 3 Study WCLC 2023 OA01.06</li> <li>Carboplatin, Etoposide, Bevacizumab, and Atezolizumab in Patients with Extensive-Stage SCLC - GOIRC-01-2019 CeLEBrATE Trial WCLC 2023 MA18.09</li> <li>A Phase 2 Study of Carboplatin, Etoposide and Nintedanib for Unresectable Small-Cell Lung Cancer with Idiopathic Pulmonary Fibrosis WCLC 2023 MA18.08</li> </ul>   <b>Dr. Santiago Ponce</b>
20 min.	<b>Líneas subsecuentes.</b>
11:00AM  (México) 6:00PM  (España)	<ul style="list-style-type: none"> <li>Reconsidering the cutoff value for sensitive and refractory relapses in extensive-stage small cell lung cancer in the era of immunotherapy DOI:10.1016/j.jtho.2023.09.1446</li> <li>Lurbinectedin (LUR) in combination with pembrolizumab (PBL) in relapsed small cell lung cancer (SCLC): the Phase 1/2 LUPER study ESMO 1989MO</li> <li>A Phase Ib/II Study of Senaparib in Combination with Low-dose Temozolomide: Updated Results in Relapsed ES-SCLC Patients WCLC 2023 MA18.11</li> <li>Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase 2 DeLLphi-301 study ESMO LBA92</li> <li>Ifinatamab Deruxtecán (I-DXd; DS-7300) in Patients with Refractory SCLC: A Subgroup Analysis of a Phase 1/2 Study WCLC 2023 OA05.05</li> </ul>   <b>Dr. Luis Paz-Ares</b>
6:20PM  (España) 10 min. 30 min.	<b>Discusión.</b>   <b>Todos</b>
	<b>Mesotelioma.</b>   Coordinador: <b>Dra. Pamela Soberanis</b>
20 min.	<b>Primera línea.</b>

## PROGRAMA

### 3er CONGRESO IBEROAMERICANO: Lo mejor en Cáncer de Pulmón 2023

11:30AM  
(México)

6:30PM  
(España)

- The IASLC Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma WCLC 2023 MA17.04 –
- IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial. ASCO LBA 8505
- MARS-2: A Multicentre Randomised Trial Comparing (Extended) Pleurectomy Decortication versus No Radical Surgery for Mesothelioma
- WCLC 2023 PL03.10 -
- No Significant Difference in Survival Between Radical Surgery and Visceral-Sparing Approach for Malignant Mesothelioma WCLC 2023 OA02.06
- Phase 1/2 Randomized Trial of Anetumab Ravtansine and Pembrolizumab Compared to Pembrolizumab for Pleural Mesothelioma WCLC 2023 OA02.04 –
- Surgical Results of EORTC 1205, a Randomized Phase II Study of Surgery for Mesothelioma Preceded or Followed by Chemotherapy WCLC 2023 MA17.06

| Dra. Noemí Reguart

10 min. ⌵

**Líneas subsecuentes.**

11:50AM  
(México)

6:50PM  
(España)

- Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study. Lancet Oncol. 2023 Oct 13:S1470-2045(23)00446-1. doi: 10.1016/S1470-2045(23)00446-1.
- First survival data from the NIPU trial; A randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma ESMO LBA99
- Bemcentinib and pembrolizumab in patients with relapsed mesothelioma: MIST3, a phase IIa trial with cellular and molecular correlates of efficacy. ASCO LBA 8511
- New pathogenic germline variants identified in mesothelioma. doi:10.1016/j.lungcan.2023.03.008

| Dra. Dolores Isla

12:00PM  
(México)

7:00PM  
(España)

10 min. ⌵

**Discusión.**

| Todos

20 min. ⌵

**Mesa de debate.**

| Coordinador: Dra. Laura Bolaño Guerra

12:10PM  
(México)

7:10PM  
(España)

**Papel de la radioterapia y cirugía en mesotelioma.**

| Dra. Noemí Reguart  
| Dra. Nuria Rodríguez de Dios  
| Dr. Marco Antonio Iñiguez García

30 min. ⌵

**Timoma y carcinoma tímico.**

| Coordinador: Dr. Suraj Samtani

20 min. ⌵

**Timoma y carcinoma tímico.**

## PROGRAMA

### 3<sup>er</sup> CONGRESO IBEROAMERICANO: Lo mejor en Cáncer de Pulmón 2023

12:30PM   
(México)

7:30PM   
(España)

- 9th Edition TNM Staging Classification: Thymic WCLC 2023 PL04.05 –
- Clinical Outcome of Patients with Thymic Carcinoma Treated with Preoperative Induction Therapy Followed by Surgical Resection WCLC 2023 P2.20-03
- The Impact of Preoperative Immunotherapy On Peri-Operative Outcomes After Thymectomy for Thymic Epithelial Tumors WCLC 2023 P2.20-05
- Combining SBRT with GM-CSF and Peg-IFN $\alpha$  to Induce Abscopal Effects in Previously Treated Patients with Stage IV Thymic Tumors WCLC 2023 MA08.05
- First-line PD-1 Inhibitor plus Chemotherapy versus Platinum-based Chemotherapy for Patients with Advanced Thymic Carcinoma WCLC 2023 MA08.08 –
- Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVANT phase II trial ESMO LBA98 - Assessment of the Quality of the Surgical Procedure and the Operative Report Based on Nationwide French Registry: A RYTHMIC study MA08.04 WCLC 2023
- STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines doi: 10.1016/j.jtho.2023.04.009.


| Dr. Xabier Mielgo


12:50PM   
(México)

**Discusión.**

7:50PM   
(España)


| Todos

10 min. 

60 min. 

**Actualización de estudios 2023: España y Latinoamérica.**

| Coordinadores: Dr. Oscar Arrieta | Dr. Felipe Couñago

25 min. 


**Actualización de estudios 2023: España.**

1:00PM   
(México)

8:00PM   
(España)

- Patterns and outcome of unplanned care in lung cancer patients: an observational study in a medical oncology department.
- Difficulties on the access to innovative targeted therapies for lung cancer in Spain.
- Immunogenicity of COVID-19 vaccines in lung cancer patients.
- Monitoring with circulating tumor cells in the perioperative setting of patients with surgically treated stages I-III NSCLC.
- A Genome-Wide Association Study of Small Cell Lung Cancer.
- Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.
- Synergy between imputed genetic pathway and clinical information for predicting recurrence in early stage non-small cell lung cancer.
- Detecting ALK, ROS1, and RET fusions and the MET $\Delta$ ex14 splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques.
- Mortality Attributable to Environmental Tobacco Smoke Exposure in Spain in 2020.
- Occupation as a risk factor of small cell lung cancer.
- Clinical factors influencing long-term survival in a real-life cohort of early stage non-small-cell lung cancer patients in Spain.
- Cost-effectiveness of diagnostic tests during follow-up in lung cancer patients: an evidence-based study.
- Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial.

| Dr. Mariano Provencio


25 min. 

**Actualización de estudios 2023: España y Latinoamérica.**



# 3<sup>er</sup> CONGRESO IBEROAMERICANO: Lo mejor en Cáncer de Pulmón 2023


1:25PM   
(México)


8:25PM   
(España)

- Mirtazapine as Appetite Stimulant in Patients With Non-Small Cell Lung Cancer and Anorexia: A Randomized Clinical Trial. JAMA Oncol. 2024 Jan 11:e235232. doi: 10.1001/jamaoncol.2023.5232.
- Molecular Tumor Board Improves Outcomes for Hispanic Patients With Advanced Solid Tumors. JCO Glob Oncol. 2024 Jan;10:e2300011. doi: 10.1200/GO.23.00011.
- Impact of Concurrent Genomic Alterations on Clinical Outcomes in Patients With ALK-Rearranged NSCLC. J Thorac Oncol. 2024 Jan;19(1):119-129. doi: 10.1016/j.jtho.2023.08.007.
- Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study. Target Oncol. 2023 May;18(3):425-440. doi: 10.1007/s11523-023-00955-9. Epub 2023 Apr 5.
- EGFR Mutation Detection in Brazilian Patients With Non-Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing. JCO Glob Oncol. 2023 Sep;9:e2200426. doi: 10.1200/GO.22.00426.
- Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer. Cancer. 2023 Feb 15;129(4):521-530.
- Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma Eur J Cancer . 2024 Jan;196:113457. doi: 10.1016/j.ejca.2023.113457.
- Nitroglycerin Plus Whole Intracranial Radiation Therapy for Brain Metastases in Patients With Non-Small Cell Lung Cancer: A Randomized, Open-Label, Phase 2 Clinical Trial Int J Radiat Oncol Biol Phys . 2023 Mar 1;115(3):592-607. doi: 10.1016/j.ijrobp.2022.02.010. Epub 2022 Feb 12.
- Real-world outcomes of anti-EGFR therapy in advanced non-small cell lung cancer EGFR mutated in Peru. Thorac Cancer. 2023

| Dr. Andrés Cardona

1:50PM   
(México)

8:50PM   
(España)

10 min. 

**Discusión.**

| Todos

2:00PM   
(México)

9:00PM   
(España)

**Despedida y cierre.**

| Dr. Oscar Arrieta  
| Dr. Felipe Couñago